
Sarepta Therapeutics (SRPT) Stock Forecast & Price Target
Sarepta Therapeutics (SRPT) Analyst Ratings
Bulls say
Sarepta Therapeutics Inc has reported a steady number of start forms for its approved treatments, indicating potential for annual sales to exceed the $500 million mark, driven by consistent adoption of its PMO products. The preliminary net revenue of $259.2 million for 4Q25, reflecting a 9% increase from the previous quarter, signifies stable market traction and suggests that recent study data have not negatively impacted payer coverage. Additionally, upcoming Ph1/2 data from new programs in 1Q26 could enhance the company’s growth prospects and reinforce confidence in its pipeline, potentially leading to further revenue increases if results support competitive profiles for its therapeutic candidates.
Bears say
Sarepta Therapeutics's recent preliminary net revenue for Elevidys in 4Q25 fell short of consensus estimates, indicating potential weaknesses in commercial performance and highlighting concerns over franchise fragility due to reliance on a small number of patient treatments. Despite management's optimism about future sales growth and a significant expansion of their salesforce, there are growing doubts regarding the efficacy and safety of Elevidys, which may hinder demand amid increasing competition from emerging therapies. Furthermore, the anticipated loss of patent protection on marketed products contributes to an unfavorable outlook, reflected in the projected 2% annual decline in revenues beyond 2026, suggesting that long-term growth prospects may be limited.
This aggregate rating is based on analysts' research of Sarepta Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Sarepta Therapeutics (SRPT) Analyst Forecast & Price Prediction
Start investing in Sarepta Therapeutics (SRPT)
Order type
Buy in
Order amount
Est. shares
0 shares